AB1132 Higher rates of obesity and associations with poorer clinical status in patients with RA, OA and SLE: a cross-sectional study from routine care

Castrejon, I.; Shakoor, Najia; Block, J.A.; Pincus, T

doi:10.1136/annrheumdis-2017-eular.3812

Cited by 3 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corticosteroids remain the first choice of treatment for SLE, but their administration is linked to excess weight gain and the development of corticosteroid-induced diabetes. Obesity was detected as an independent risk factor in worsening the functional capacity, fatigue, and inflammation status of patients with SLE ( 20 , 22 – 24 ).…”

Section: Macronutrientsmentioning

confidence: 99%

Immunomodulatory Effects of Diet and Nutrients in Systemic Lupus Erythematosus (SLE): A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement, including the skin, joints, kidneys, lungs, central nervous system and the haematopoietic system, with a large number of complications. Despite years of study, the etiology of SLE remains unclear; thus, safe and specifically targeted therapies are lacking. In the last 20 years, researchers have explored the potential of nutritional factors on SLE and have suggested complementary treatment options through diet. This study systematically reviews and evaluates the clinical and preclinical scientific evidence of diet and dietary supplementation that either alleviate or exacerbate the symptoms of SLE. For this review, a systematic literature search was conducted using PubMed, Scopus and Google Scholar databases only for articles written in the English language. Based on the currently published literature, it was observed that a low-calorie and low-protein diet with high contents of fiber, polyunsaturated fatty acids, vitamins, minerals and polyphenols contain sufficient potential macronutrients and micronutrients to regulate the activity of the overall disease by modulating the inflammation and immune functions of SLE.

show abstract

Section: Macronutrientsmentioning

confidence: 99%

Immunomodulatory Effects of Diet and Nutrients in Systemic Lupus Erythematosus (SLE): A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Objectives: With the present study we aimed to assess the clinical usefulness of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) [3] for risk stratification of thrombosis relapse and/or progression of known ischaemic lesions dectected with Magnetic Resonance Imaging (MRI) in a cohort of young adult APS patients.…”

Section: Discussionmentioning

confidence: 99%

AB1130 Relapse risk assessment in young aps patients with previous stroke event using the adjusted global antiphospholipid syndrome score (AGAPSS)

Cecchi¹,

Radin²,

Schreiber

et al. 2017

Abstracts Accepted for Publication

View full text Add to dashboard Cite

BackgroundThe most frequent manifestation of arterial thrombosis in patients affected by Antiphospholipid syndrome (APS) is ischaemic stroke, especially in young adults (less than 50 years old) [1]. Young adults affected by APS are a group of patients at greater risk of developing serious stroke events and recurrences of thrombosis. Therefore, risk stratification in this particular group is crucial, especially in order to prevent a recurrence of ischaemic thrombotic event.ObjectivesWith the present study we aimed to assess the clinical usefulness of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) [3] for risk stratification of thrombosis relapse and/or progression of known ischaemic lesions dectected with Magnetic Resonance Imaging (MRI) in a cohort of young adult APS patients.MethodsThe analysis included 80 APS patients (≤50 years old) who presented a previous stroke event (patients who experienced cerebral venous sinus thrombosis were not included in the analysis). Clinical and laboratory data were retrospectively collected. Treatment was based on phisician's opinion according to clinical settings. The aGAPSS was calculated for each patient by adding the points corresponding to the risk factors, based on a linear transformation derived from the β regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for antiβ2glycoprotein I IgG/IgM and 4 for LA. Relapse was defined as the recurrence of thrombotic event and/or progression of known ischaemic lesions detected with MRI.ResultsResults pointed out that patients with relapse of thrombotic events and/or progression of known ischaemic lesions were 39 out of 80 (48.7%) and patients without relapse were 41 out of 80 (51.3%). Significantly higher aGAPSS values were observed in relapse group when compared to the non-relapse group [mean aGAPSS 9.08 (S.D. 4.7) Vs. mean aGAPSS 7.22 (S.D. 3.3); T test: p<0.05]. Distribution of aGAPPS values among the two groups is illustrated in Graph 1.ConclusionsOur analysis suggests that aGAPSS could represent an effective tool to stratify the risk of relapse of thrombosis and/or progression of ischaemic lesions in young APS patients with clinical history of stroke. These data could also aid developing different therapeutic approaches, especially for patients at higher risk of relapse.References Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006;166(20):2278–84.Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330–9.Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013; 52:1397–403. AcknowledgementsNone.Disclosure of InterestNone declared

show abstract

“…In OA, obesity is a risk factor for both incidence and progression, and has a negative impact on outcomes 2 . In systemic lupus erythematous (SLE), obesity is associated with more severe renal involvement, lower quality of life, and increased cardiovascular risk 3 . Objectives: To assess associations of obesity with patient self-report multidimensional health assessment questionnaire (MDHAQ) scores and physician global assessments in patients with RA, OA and SLE seen in routine care.…”

mentioning

confidence: 99%

AB1132 Higher rates of obesity and associations with poorer clinical status in patients with RA, OA and SLE: a cross-sectional study from routine care

Castrejon

Shakoor

Block

et al. 2017

Abstracts Accepted for Publication

Self Cite

View full text Add to dashboard Cite

BackgroundObesity is a risk factor for many chronic rheumatic diseases. In rheumatoid arthritis (RA), obesity is associated with increased comorbidities, higher medical costs, disease activity, and poorer physical function1. In OA, obesity is a risk factor for both incidence and progression, and has a negative impact on outcomes2. In systemic lupus erythematous (SLE), obesity is associated with more severe renal involvement, lower quality of life, and increased cardiovascular risk3.ObjectivesTo assess associations of obesity with patient self-report multidimensional health assessment questionnaire (MDHAQ) scores and physician global assessments in patients with RA, OA and SLE seen in routine care.MethodsAll patients at one academic center complete a MDHAQ, which includes a 0–10 scale for physical function (FN), 0–10 visual analogue scales (VAS) for pain (PN) and patient global assessment (PATGL), compiled into a 0–30 RAPID3, as well as scales for fatigue, depression, and demographic data. Physicians complete a VAS for patient global (DOCGL). Body Mass Index (BMI) was calculated from the medical record as weight (kg)/ height (meters)2. Patients were classified by BMI as normal (18.5–25), overweight (25–30), or obese (>30) according to the WHO guidelines. Demographic and clinical MDHAQ data were compared in the 3 diagnostic groups according to BMI groups using ANOVA and chi-square tests.Results396 patients with RA, 425 with OA, and 306 with SLE were studied. Obesity was reported by 40% of RA and SLE patients, and 59% of OA patients, a higher percentage than matched individuals in the general population in the same region (30.8%). Obesity was higher in African-American patients (48% in RA, 70% in OA, and 53% in SLE). Education level, gender, and age did not differ significantly across the groups. Obesity was associated with poorer physical function, poorer patient global and higher pain in all 3 diagnostic groups, with higher depression scores in OA and SLE (Table). DOCGL was significantly higher only in OA (data not shown).Table 1.MDHAQ scores and physician global assessment according to BMI groupsMDHAQ scoresNormal (BMI=18.5–25)Overweight (BMI=25–30)Obesity (BMI>30) RA (N=381)110 (29%)112 (30%)154 (40%) Function (0–10)2.1 (2.2)2.4 (2.2)2.9 (2.0)* Pain (0–10)4.4 (2.8)4.6 (3.0)5.1 (3.1)* Fatigue (0–10)3.4 (2.9)3.6 (3.1)4.5 (3.2)* PATGL (0–10)3.8 (2.7)4.1 (3.1)4.8 (2.8)* Depression (0–3.3)0.5 (0.7)0.5 (0.7)0.6 (0.8)OA (N=420)60 (14%)102 (24%)247 (59%) Function (0–10)1.7 (1.5)2.6 (1.8)3.2 (2.0)* Pain (0–10)5.1 (2.9)6.7 (2.5)6.6 (2.6)* Fatigue (0–10)3.4 (2.9)4.3 (2.9)5.3 (3.1)* PATGL (0–10)4.5 (3.1)5.7 (2.5)5.9 (2.7)* Depression (0–3.3)0.4 (0.6)0.6 (0.8)0.7 (0.8)*SLE (N=299)84 (28%)85 (28%)121 (40%) Function (0–10)1.4 (1.5)1.2 (1.6)2.3 (2.1)* Pain (0–10)3.5 (3.2)3.9 (3.1)5.2 (3.3)* Fatigue (0–10)4.2 (3.3)4.2 (3.4)5.1 (3.2) PATGL (0–10)3.6 (2.9)3.9 (3.1)4.6 (3.2)* Depression (0–3.3)0.4 (0.6)0.4 (0.6)0.7 (0.8)**p<0.01.ConclusionsObesity is more prevalent in patients with rheumatic diseases compared with the general popul...

show abstract

AB1132 Higher rates of obesity and associations with poorer clinical status in patients with RA, OA and SLE: a cross-sectional study from routine care

Cited by 3 publications

References 1 publication

Immunomodulatory Effects of Diet and Nutrients in Systemic Lupus Erythematosus (SLE): A Systematic Review

Immunomodulatory Effects of Diet and Nutrients in Systemic Lupus Erythematosus (SLE): A Systematic Review

AB1130 Relapse risk assessment in young aps patients with previous stroke event using the adjusted global antiphospholipid syndrome score (AGAPSS)

AB1132 Higher rates of obesity and associations with poorer clinical status in patients with RA, OA and SLE: a cross-sectional study from routine care

Contact Info

Product

Resources

About